Clinical Trial Update: Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing oral ibrexafungerp (SCY-078) to standard-of-care after IV echinocandin in invasive candidiasis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• Ibrexafungerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Mycoses, Candidiasis, Invasive | Phase 2 | Status: COMPLETED | Results posted: 2024-06-25